In the wake of its high-pro­file set­back in heart dis­ease late last week, No­var­tis re­al­ly need­ed a win. It didn’t get one. The Swiss phar­ma said Tues­day that in a late-stage tri­al, an an­ti­body-oligonu­cleotide con­ju­gate that it got from Avid­i­ty was not sta­tis­ti­cal­ly sig­nif­i­cant­ly bet­ter than place­bo in pa­tients with a neu­ro­mus­cu­lar dis­ease called my­oton­ic dy­s­tro­phy type 1 (DM1)...